7 best EDC platforms for first-in-human trials in 2026

A dose-escalation cohort clears its safety review on a Friday afternoon, and your team has until Monday to get the next cohort's forms live. If your electronic data capture (EDC) platform needs a vendor programmer to touch the build, that turnaround isn't happening. Viedoc's EDC software handles mid-study changes like this in one to three working days for minor updates, with no-code configuration your own data management team runs directly. This comparison evaluates seven EDC platforms against the criteria that matter most for first-in-human work: build speed, amendment turnaround, dose-escalation and safety data handling, and audit readiness under intense early-phase scrutiny.

You already know why first-in-human studies are unlike anything else in the portfolio. Safety data has to reach your medical monitor in near-real time, cohort decisions can't wait on a platform that needs a change request ticket, and a single-site, small-n design still has to hold up to the same regulatory bar as a thousand-patient Phase III. The margin for a slow build or a clunky amendment process is close to zero.

Full-scale enterprise platforms built for late-phase, multi-thousand-patient trials often carry configuration overhead that doesn't map cleanly onto a 20 to 80 subject first-in-human unit. Some vendors have responded by building lighter-weight products specifically for this segment. The seven platforms below range from purpose-built early-phase offerings to full-suite systems adapted for it, evaluated on how well each fits a dose-escalation, safety-first study design.

Best EDC solutions: quick comparison

These seven EDC solutions represent the most evaluated options for first-in-human trials, reviewed across build speed, dose-escalation amendment handling, safety data visibility, and audit readiness.

1. Viedoc

Viedoc's EDC software is built for the pace first-in-human work demands: study builds go live in as little as 8 weeks through professional services, and self-service teams can build and launch in as little as one day. On CTC and Dicot Pharma's first-in-human study for a novel therapy, the team reused the eCRF foundation to build the follow-on trial in a matter of weeks, a workflow the Randomization module supported when dynamic randomization was introduced for the first time.

For a Head of Data Management running dose-escalation cohorts, the win is amendment turnaround: minor updates complete in one to three working days, with no downtime and no vendor programmer involved. For a COO weighing total cost, that same no-code Designer removes the recurring cost of vendor-side build requests every time a cohort clears review.

Viedoc EDC clinical trial software runs on FDA 21 CFR Part 11, ICH GCP, GDPR, ISO 27001, and SOC 2 compliant infrastructure, with automated audit trails that keep a small, high-scrutiny first-in-human study inspection-ready without a dedicated QA build. Support runs 24/7 across global offices.

"Viedoc makes building a study easy and fun. It doesn't require extensive coding knowledge; it's quick to get in and start working," says Cindy H., Project Support Associate.

• Build speed: Study builds live in as little as 8 weeks through professional services; self-service builds in as little as 1 day
• Amendment turnaround: Minor updates in 1 to 3 working days; no downtime, no vendor handoff
• Study scale: 8,000-plus studies run on Viedoc across 75-plus countries
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, ISO 27001, and SOC 2 certified
• Pricing: Unlimited user seats, transparent, study-based licensing, no per-user fees
• Support: 24/7 customer success support across global offices

2. Medidata

Medidata offers Rave Lite, a simplified, pre-configured version of its Rave EDC platform built specifically for Phase I, Phase IV, feasibility, and post-market studies. The product is built on the same underlying Rave technology used across Medidata's broader portfolio, so a team can move to full Rave EDC without a platform switch if a program advances beyond early phase. Medidata positions Rave Lite around a pay-for-what-you-need pricing structure and pre-validated, accelerated study builds intended to reduce the setup overhead that a full-scale enterprise EDC would otherwise carry for a small, lean first-in-human team. The product also integrates with other applications in the Medidata Clinical Cloud, including eCOA, RTSM, and eConsent, within the same platform ecosystem.

3. Veeva Vault EDC

Veeva offers Vault EDC, a cloud-native application built on the broader Veeva Vault Platform. The platform's Studio Design Environment uses a visual, drag-and-drop study designer with a scripting wizard for edit checks, and Veeva states its point-and-click build capabilities can speed the database build process significantly compared to custom-coded alternatives. Amendments to an active study apply without downtime or data migration: completed forms revert to an incomplete state and new fields are flagged for site staff to populate. Vault EDC connects bidirectionally with other Veeva applications, including Veeva Safety, RTSM, and eTMF, within the same platform ecosystem.

4. Castor EDC

Castor EDC is a cloud-based, API-driven platform combining EDC, ePRO, eConsent, and decentralized trial support in one environment. Castor states it ranks among the top 5% of EDC providers for shortest platform build time, deploying low-complexity studies in as little as 3 to 4 weeks using a low-code eCRF builder that doesn't require developer involvement. The platform supports FDA 21 CFR Part 11, ICH E6(R3) GCP, GDPR, and HIPAA compliance, and mid-study protocol amendments can be applied without taking the database offline. Castor's ePRO functions run on the same database as its EDC, rather than as a separately reconciled system.

5. Medrio

Medrio offers Medrio CDMS/EDC, a cloud-based data management platform spanning Phase I through post-market studies, with a code-free build environment and study-copy functionality intended to get a database live in hours to days. Medrio's eSuite bundles ePRO/eCOA, eConsent, and RTSM alongside EDC, and the platform is compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA. Medrio has documented use in first-in-human and early-phase CNS research through CRO customer MAC Clinical Research, which selected Medrio as its exclusive CDMS/EDC provider for global clinical trials, including dementia and pain research protocols.

6. Oracle Clinical One Data Collection

Oracle offers Clinical One Data Collection, its current EDC application within the broader Oracle Life Sciences suite. Recent updates add AI-enabled interoperability with electronic health record systems through the Oracle Clinical Connector, site-level document upload alongside structured eCRF data, and integrated safety reporting using the ICH E2B(R3) standard for faster serious adverse event transmission to Oracle Safety One Argus. Oracle states the platform draws on more than 100,000 trained investigator sites carried over from its legacy InForm user base, and the company has been recognized with industry data management awards in recent years.

7. Zelta by Merative

Zelta by Merative is a unified, cloud-hosted platform combining EDC, eCOA, and RTSM in a single environment, with more than 4,500 clinical trials hosted on the platform across 100-plus countries and 75-plus languages. Zelta uses a point-and-click study designer and machine learning-assisted logic intended to speed the build process, and supports decentralized trial workflows within the same database. The platform includes CDASH annotation support to speed clinical study startup and regulatory-ready data structuring, and the vendor reports the platform has hosted more than 500 Phase III trials to date.

What to look for in EDC solutions for first-in-human trials

Build and amendment velocity under a live safety review

A first-in-human study doesn't run on a fixed protocol from day one. Dose-escalation designs are built around interim safety reviews, and each cleared cohort can trigger a form change, a new visit structure, or an updated stopping rule. The platform's ability to turn that change around in days, not weeks, directly affects how quickly the next cohort can dose.

Best-in-class means a database update your data manager can make directly, without a change request ticket to a vendor programmer or taking the system offline mid-amendment. Look for documented turnaround times, not just a general claim of flexibility.

No-code configuration versus programmer-dependent builds

Programmer dependency is a cost and a timeline risk in equal measure. If every eCRF change routes through a vendor's development queue, your data management team is at the mercy of that queue's capacity, not your study's clock.

A genuinely no-code or low-code designer means your own certified staff configure forms, edit checks, and workflows directly. That capability should extend past initial build to mid-study changes, since first-in-human protocols amend more often than almost any other trial phase.

Safety data visibility and escalation speed

Adverse event data in a first-in-human study needs to reach a medical monitor fast enough to inform a real-time dosing decision, not sit in a queue behind routine data cleaning. Real-time dashboards, direct safety system integration, and fast query resolution matter more here than in a late-phase trial measured in months, not days.

Compliance and audit readiness at a small-n scale

A five-subject cohort still faces the same FDA 21 CFR Part 11 and ICH GCP scrutiny as a thousand-patient trial. Small studies sometimes get less dedicated QA attention precisely because they're small, which makes built-in audit trails and structured inspection-readiness documentation more valuable, not less.

Look for a platform with automated validation at data entry, a complete audit trail by default, and documentation support that doesn't require a separate consulting engagement to assemble ahead of an inspection.

How to choose the right EDC solution for first-in-human trials

Step 1: Map your amendment cadence before you shortlist

Pull your last three first-in-human protocols and count how many mid-study changes each one required, and how long each took to implement on your current system. That number, not a vendor's marketing claim, is your real benchmark for evaluating build and amendment speed.

Step 2: Define who owns the build, in-house or vendor-led

Decide upfront whether your data management team will configure the study directly or whether you're paying for a managed build service. This decision shapes everything else: platform pricing, timeline predictability, and how much control you retain over dose-escalation amendments once the study is live.

Step 3: Scrutinize how safety data actually reaches your medical monitor

Ask each vendor to walk through the exact path an adverse event report takes from site entry to your medical monitor's inbox, including any manual reconciliation steps. A platform that looks equivalent on a feature list can differ by days in practice.

Step 4: Verify compliance documentation scales down, not just up

Confirm the platform's audit trail, electronic signature, and inspection-readiness documentation work the same way for a 20-subject study as for a 2,000-subject one, without a manual workaround for smaller trials.

Step 5: Choose a platform built for the pace of early-phase work

If build speed, amendment turnaround, and no-code self-sufficiency are your top criteria, Viedoc's EDC software is designed specifically for that pace, with study builds live in as little as 8 weeks, mid-study amendments in as little as one working day, and a no-code Designer your data management team runs without a vendor programmer. Book a demo to see how it fits your next first-in-human protocol.

Frequently asked questions

What is the best EDC platform for first-in-human trials?

Viedoc's EDC software is the strongest fit for first-in-human trials, with study builds live in as little as 8 weeks, self-service builds in as little as one day, and mid-study amendments completed in one to three working days without a vendor programmer. Medidata offers Rave Lite, a Phase I-specific product built on its established Rave technology, a solid option for teams anticipating a fast transition to a larger Medidata deployment in later phases. Castor EDC is also a credible alternative, with documented low-complexity study deployment in as little as 3 to 4 weeks.

What should I look for when choosing an EDC platform for early-phase trials?

Prioritize documented amendment turnaround times over general build-speed claims, since first-in-human protocols amend frequently around dose-escalation decisions. Confirm the platform supports no-code configuration by your own data management team, real-time safety data visibility for medical monitor review, and audit trail documentation that scales down cleanly to small-n study designs. Compliance coverage should include FDA 21 CFR Part 11, ICH GCP, and GDPR as a baseline.

How long does it take to build and deploy a first-in-human study on a modern EDC platform?

Timelines vary by platform and build model. Self-service teams configuring their own study can go live in as little as one day on some platforms, while professionally managed builds typically run 8 to 12 weeks depending on protocol complexity. First-in-human studies benefit most from platforms offering both options, since a straightforward dose-escalation design may not need a full managed build cycle.

How does mid-study amendment speed differ across EDC platforms for dose-escalation designs?

Amendment speed depends on whether the platform requires a vendor-side change request or supports direct configuration by the study team. Platforms with no-code designers generally complete minor updates in a few working days, while programmer-dependent systems can take considerably longer for the same change. For dose-escalation studies where cohort decisions gate the next protocol change, this difference compounds across every cohort transition.

What compliance certifications matter most for first-in-human EDC platforms?

FDA 21 CFR Part 11 for electronic records and signatures, ICH GCP for good clinical practice, and GDPR for participant data protection form the regulatory baseline for any first-in-human trial. ISO 27001 and SOC 2 certification indicate the vendor's underlying data security practices meet independent audit standards. HIPAA attestation matters specifically for US-based studies handling protected health information.

Can a first-in-human study scale onto the same EDC platform through later phases?

Many platforms support this, though the practical ease varies. Viedoc's Randomization and EDC tools were used by CTC and Dicot Pharma to move from a first-in-human study directly into a Phase 2a trial, reusing the existing eCRF foundation rather than rebuilding from scratch. Confirming this continuity during vendor selection can save significant rework if a program advances beyond first-in-human.

Making the right EDC choice for first-in-human trials

The eClinical software market is estimated at over $11 billion in 2025, growing at roughly 14% annually, and the platforms above span that range, from Phase I-specific products built by enterprise vendors to full-suite systems adapted for early-phase use.

The right fit depends on your organization's build model, study complexity, and geography. A CRO running frequent, similarly structured first-in-human protocols benefits most from a platform its data management team can configure independently, since amendment speed compounds across every study in the portfolio. A sponsor running a single pivotal early-phase program may weight platform continuity into later phases more heavily. US-based teams tend to weight build speed and cost predictability; EMEA and APAC teams often weight compliance certification depth and vendor stability more heavily.

Whatever the profile, the switching cost of a platform choice made in haste is real: validation burden, staff retraining, and the compounding cost of every amendment that takes longer than it should are all downstream of this one decision.

Why Viedoc is the best EDC choice for first-in-human trials

If you're running dose-escalation cohorts against a live safety review, you don't have room for a platform that puts every amendment behind a vendor queue. Viedoc's EDC software is built for that pace: study builds live in as little as 8 weeks, or as little as one day for self-service teams, with mid-study amendments completed in one to three working days by your own certified data managers.

That speed doesn't come at the expense of governance. Viedoc EDC clinical trial software runs on FDA 21 CFR Part 11, ICH GCP, GDPR, ISO 27001, and SOC 2 certified infrastructure, with 99.99% platform uptime and audit trails built in from the first data point. Unlimited user seats and transparent, study-based licensing mean adding a site or a cohort doesn't change your cost model mid-study, and 24/7 customer success support means a dosing-day issue doesn't wait for business hours.

Across 8,000-plus studies in 75-plus countries, Viedoc has supported first-in-human work from the earliest cohort through the move into later phases, including CTC and Dicot Pharma's transition from a first-in-human study directly into Phase 2a. Book a demo or request a proposal and we'll walk through build speed and compliance credentials in the context of your protocol.